Examkin

Question

Difficulty: MediumGynecologic Infections

During a routine follow-up visit at the community health center, a 26-year-old G2P2 woman complains of deep pelvic pain with intercourse and a new-onset, foul-smelling vaginal discharge over the past week. Her medical history includes the insertion of a copper intrauterine device (IUD) 18 months ago. Vital signs are within normal limits except for a temperature of 38.1°C (100.6°F). On bimanual examination, there is marked tenderness upon moving the cervix and bilateral adnexal fullness with guarding, but no discrete mass is palpated. A point-of-care urine pregnancy test is negative. Which of the following is the most appropriate next step in the management of this patient's condition?

  1. Leave the intrauterine device in place and prescribe intramuscular ceftriaxone, along with a 14-day course of oral doxycycline and metronidazoleAnswer
  2. B
    Remove the intrauterine device immediately and prescribe intramuscular ceftriaxone, along with a 14-day course of oral doxycycline and metronidazole
  3. C
    Withhold antimicrobial therapy pending the results of cervical nucleic acid amplification testing
  4. D
    Admit the patient to the hospital for intravenous cefotetan and doxycycline, and leave the intrauterine device in place
  5. E
    Leave the intrauterine device in place and prescribe a 7-day course of oral metronidazole monotherapy

Answer

Leave the intrauterine device in place and prescribe intramuscular ceftriaxone, along with a 14-day course of oral doxycycline and metronidazole.
The correct approach is to prescribe intramuscular ceftriaxone, oral doxycycline, and oral metronidazole, while leaving the intrauterine device in place. The patient's clinical presentation of deep pelvic pain, fever, abnormal vaginal discharge, and cervical motion tenderness is highly indicative of pelvic inflammatory disease (PID). The most appropriate next step is to initiate empiric outpatient therapy with intramuscular ceftriaxone to cover Neisseria gonorrhoeae, oral doxycycline to cover Chlamydia trachomatis, and oral metronidazole to cover anaerobic organisms. According to current guidelines, an intrauterine device (IUD) does not need to be removed in patients with mild-to-moderate PID unless there is no clinical improvement after 48 to 72 hours of appropriate broad-spectrum antimicrobial therapy.

Step-by-Step Solution

1
Identify the primary clinical syndrome based on the patient's presentation.
The patient presents with fever, lower abdominal pain, abnormal vaginal discharge, and cervical motion tenderness.
Recognizing this classic triad establishes the clinical diagnosis of Pelvic Inflammatory Disease (PID).
2
Determine the appropriate setting for treatment (inpatient vs. outpatient).
The patient lacks criteria for hospitalization (e.g., she is not pregnant, has no severe nausea/vomiting, and has no discrete palpable tubo-ovarian abscess).
Outpatient management is the standard of care for patients with mild-to-moderate PID.
3
Select the optimal outpatient antimicrobial regimen and determine the management of the intrauterine device (IUD).
Standard therapy requires intramuscular ceftriaxone plus oral doxycycline and metronidazole; the IUD should be left in place.
Broad-spectrum coverage for N. gonorrhoeae, C. trachomatis, and anaerobes is necessary. IUD removal does not hasten recovery in initial management and is only indicated if the patient fails to respond within 48 to 72 hours.

Key Concept

Outpatient management of Pelvic Inflammatory Disease (PID) in a patient with an intrauterine device (IUD).
Rate this question

Topics

Gynecologic Infections

More questions from this topic